Results 221 to 230 of about 349,122 (350)

Temporal trends in chronic diseases among offshore oil workers and the interaction effect of age with body mass index. [PDF]

Front Public Health
Li J, Hu M, Wang T, Xie Y, Liu Y, Yao J, Hua G, Yan X, Fan H.   +8 more
europepmc   +1 more source

Treatment of dyslipidemia in acute coronary syndrome

Satyavir Yadav, J.P.S. Sawhney
openalex   +1 more source

Polymorphisms of the ApoE (Apolipoprotein E) Gene and Their Influence on Dyslipidemia in HIV-1-Infected Individuals

, 2014
Tanida Suwalak, Pornpen Srisawasdi, Apichaya Puangpetch, Siwalee Santon, Napatrupron Koomdee, Monpat Chamnanphon, Angkana Charoenyingwattana, Wasun Chantratita, Chonlaphat Sukasem   +8 more
openalex   +2 more sources

Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction‐associated steatotic liver disease treated with semaglutide: A case series

JPGN Reports, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects 30%–40% of youth with obesity and lacks approved pharmacologic therapies. In this single‐center retrospective case series at a tertiary care safety‐net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index:
Rachel Schenker, Katya Fomenko, Fotini T. Mitsinikos, Alaina P. Vidmar   +3 more
wiley   +1 more source

Maintaining Cardiovascular Health in Patients With Mixed Dyslipidemia Optimizing the Management of Hypertriglyceridemia and Non-HDL Cholesterol [PDF]

, 2009
Matthew K. Ito, James M. McKenney, Eliot A. Brinton   +2 more
openalex   +1 more source

Hepatopulmonary syndrome as presentation of pediatric metabolic dysfunction‐associated steatohepatitis

JPGN Reports, EarlyView.
Abstract Childhood obesity is rising and leading to serious co‐morbidities, among which is metabolic dysfunction‐associated steatotic liver disease (MASLD) predisposing individuals to cirrhosis. We describe a young 11‐year‐old Hispanic male who presented with hepatopulmonary syndrome secondary to cirrhotic portal hypertension from metabolic dysfunction‐
Shruti Sakhuja, Stacey S. Beer, Kalyani R. Patel, Alexiss M. Williams, Nhu Thao Galvan, John A. Goss, Krupa R. Mysore   +6 more
wiley   +1 more source

Gut Microbiota and Metabolomics Insights into the Gualou-Xiebai Herb Pair for Dyslipidemia and Atherosclerosis. [PDF]

J Microbiol Biotechnol
Wang N, Xu Y, Li J, Li C, Liu Z, Li Z, Liu Y, Zhang Y, Zhou A, Wu H.   +9 more
europepmc   +1 more source

Associations between the age at surgical repair in patients with abdominal aortic aneurysms and aortoiliac occlusive disease and smoking and dyslipidemia with reference to PON1–108C>T genotype

, 2008
Ewa Strauss, Krzysztof N. Waliszewski, W Majewski, A.L. Pawlak   +3 more
openalex   +1 more source

429: Risk for developing chronic hypertension, dyslipidemia, and diabetes after preeclampsia [PDF]

, 2019
Jessica Spiegelman, Shravya Govindappagari, Sbaa Syeda, Timothy Wen, Yongmei Huang, Mary E. D’Alton, Kirsten Cleary, Jason D. Wright, Alexander M. Friedman   +8 more
openalex   +1 more source

The Impact of Methotrexate on Cardiovascular Outcomes in Psoriasis: A Systematic Review and Meta‐Analysis

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic immune‐mediated inflammatory disease with a global prevalence of 2%–3% and 1.3% in Brazil. It is associated with comorbidities such as obesity, hypertension, and diabetes, all of which contribute to increased cardiovascular risk due to systemic inflammation and endothelial dysfunction.
Tiago A. S. Costa, Sheila T. K. Medorima, Renata F. Magalhães   +2 more
wiley   +1 more source